Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crinecerfont in Pediatric Subjects 0 to <2 Years With Congenital Adrenal Hyperplasia
NCT07187375Phase 2Active, not recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Sep 2025
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crinecerfont in congenital adrenal hyperplasia (CAH), sponsored by Neurocrine Biosciences. Primary endpoint: Plasma Concentration of Crinecerfont at Day 15. Started Sep 2025; status: active, not recruiting.
02
Drugs
crinecerfont
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT07187375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187375.